<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36112355</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Effect of difference between EV-A71 virus epidemic strain and "vaccine strain" on neutralizing antibody titer.</ArticleTitle><Pagination><StartPage>2121565</StartPage><MedlinePgn>2121565</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2121565</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2022.2121565</ELocationID><Abstract><AbstractText>Hand, foot and mouth disease was mainly caused by EV-A71 virus. The main antigen structure of VP1 region of EV-A71 was easily varied. Here, we investigated the seroprevalence of EV-A71 based on a large group of healthy individuals in Beijing, China, in order to study the effectiveness of EV-A71 vaccine in a real-world setting. BrCr and the clinical strain isolated from the Chinese mainland in 2008 ("vaccine strain:"CMU4232/BJ/CHN/2008), EV-A71 C4 epidemic strains isolated in 2010, 2013, and 2016, were tested for neutralizing antibodies (NtAb) in every year. Phylogenetic tree analysis of the EV-A71 strains above, as well as amino acid composition homologous sequence analysis were applied. The "vaccine strain" has 83.0% homology with FY23, H07 and FY7VP5. It belongs to the same branch of C4a as 10 C4, 13 C4 and 16 C4, and differs from the amino acid sites 283 and 293 of 16 C4. Compared with "vaccine strains," there was a significant difference between the 50-59&#x2009;years old age group when the NtAb titer of 16 C4 strain was 1:512-1:1024. Our results suggest that changes in the functional epitopes of NtAb caused by amino acid 283 and 293 loci in EV-A71 strains may affect the production of neutralizing antibodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Yiwei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, the Sixth Medical Center of PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Zhihai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, the Sixth Medical Center of PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HFMD EV-A71</Keyword><Keyword MajorTopicYN="N">NtAb vaccine</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36112355</ArticleId><ArticleId IdType="pmc">PMC9746541</ArticleId><ArticleId IdType="doi">10.1080/21645515.2022.2121565</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ishimaru Y, Nakano S, Yamaoka K, Takami S.. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system[J]. Arch Dis Child. 1980;55:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1627055</ArticleId><ArticleId IdType="pubmed">6254449</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71[J]. Lancet Infect Dis. 2010;10:778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FGL, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the outbreak study group[J]. Clin Infect Dis. 2000;31(3):678&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance[J]. FEMS Microbiol Rev. 2002;26:91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J. Enterovirus 71 infection: a new threat to global public health?[J]. Lancet Neurol. 2008;7:868&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128195</ArticleId><ArticleId IdType="pubmed">18848307</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JMG, Li W, Huang Z, Lu S. EV71: an emerging infectious disease vaccine target in the far East?[J]. Vaccine. 2010;28:3516&#x2013;3521.</Citation><ArticleIdList><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Tu P, Thao N, Perera D, Truong KH, Tien NTK, Thuong TC, How OM, Cardosa MJ, McMinn PC. Epidemiologic and virologic investigation of hand, foot, and mouth disease, Southern Vietnam, 2005[J]. Emerg Infect Dis. 2007;13:1733&#x2013;1741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375788</ArticleId><ArticleId IdType="pubmed">18217559</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children[J]. N Engl J Med. 2014;370(9):829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sanden S, Koopmans M, Uslu G, van der Avoort H. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008[J]. J Clin Microbiol. 2009;47:2826&#x2013;2833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738086</ArticleId><ArticleId IdType="pubmed">19625480</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang P, Chen S, Chen K, The Current Status of the Disease Caused by Enterovirus 71 Infections: Epidemiology, Pathogenesis, Molecular Epidemiology, and Vaccine Development[J]. IJERPH.2016;13(9):890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China[J]. Virol J. 2010;7(1):94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Mao QY, Liang ZL, Ji H, Zhu F-C. Development of enterovirus 71 vaccines: from the lab bench to phase III clinical trials[J]. Expert Rev Vaccines. 2014;13:609&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">24621093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of Hand, Foot and Mouth Disease (HFMD)[J]. Expert Rev Vaccines. 2016;15:599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki K, Okuno Y. Genetic diagnosis and molecular epidemiological analyses of hand, foot and mouth disease which prevailed in osaka prefecture in 2000][J]. Kansenshogaku Zasshi. 2001;75:909&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">11766373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi EE, Phoon MC, Ishak B, Chan S-H. Seroepidemiology of human enterovirus 71, Singapore[J]. Emerg Infect Dis. 2002;8:995&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732542</ArticleId><ArticleId IdType="pubmed">12194783</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Yi L, Su J, Lu J, Ke C, Zeng H, Guan D, Ma C, Zhang W, Xiao H, et al. Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period[J]. PLoS One. 2013;8(12):e80515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850913</ArticleId><ArticleId IdType="pubmed">24324604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, El KN, Tu S, Ren P, Xu S, Zhu Q, Mo X, Pu D, Wang X, Altmeyer R, et al. Seroepidemiology of enterovirus 71 infection prior to the 2011 season in children in Shanghai[J]. J Clin Virol. 2012;53(4):285&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Zhu S, Guo X, Wang J, Wang D, Yan D, Tan X, Tang L, Zhu H, Yang Z, et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008[J]. Virol J. 2010;7(1):300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989968</ArticleId><ArticleId IdType="pubmed">21050463</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, Chang Z, Liu F, Fang VJ, Zheng Y, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study[J]. Lancet Infect Dis. 2014;14(4):308&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Wang H, Lu Y, Li Q, Chen C, Wang D, Li M, Li Y, Lu J, Chen Z, et al. Willingness and influential factors of parents to vaccinate their children with novel inactivated enterovirus 71 vaccines in Guangzhou, China[J]. Vaccine. 2018;36(26):3772&#x2013;3778.</Citation><ArticleIdList><ArticleId IdType="pubmed">29776754</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Cheng HL, Hsieh HY, Chang C-L, Tsai H-P, Kuo P-H, Wang S-M, Liu C-C, Su I-J, Wang J-R, et al. Mutations in the non-structural protein region contribute to intra-genotypic evolution of enterovirus 71[J]. J Biomed Sci. 2014;21(1):33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4021180</ArticleId><ArticleId IdType="pubmed">24766641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zeng G, Chu K, Zhang J, Han W, Zhang Y, Li J, Zhu F. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation[J]. Hum Vaccin Immunother. 2018;14(6):1517&#x2013;1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6037439</ArticleId><ArticleId IdType="pubmed">29482422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Kong Y, Jiang Z, Li C, Wang L, Xia J. Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial[J]. Hum Vaccin Immunother. 2016;12(4):922&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962949</ArticleId><ArticleId IdType="pubmed">26837471</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, Lin KH, Wang SM, Liu CC, Su IJ, Wang JR. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008[J]. J Clin Microbiol. 2009;47(11):3653&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Noisumdaeng P, Sangsiriwut K, Prasertsopon J, Klinmalai C, Payungporn S, Mungaomklang A, Chokephaibulkit K, Buathong R, Thitithanyanont A, Puthavathana P.. Complete genome analysis demonstrates multiple introductions of enterovirus 71 and coxsackievirus A16 recombinant strains into Thailand during the past decade[J]. Emerg Microbes Infect. 2018;7(1):214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6294798</ArticleId><ArticleId IdType="pubmed">30552334</ArticleId></ArticleIdList></Reference><Reference><Citation>Martcheva M, Bolker BM, Holt RD. Vaccine-induced pathogen strain replacement: what are the mechanisms?[J]. J R Soc Interface. 2008;5:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2405901</ArticleId><ArticleId IdType="pubmed">17459810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Podin Y, Akin W, Del Sel S, Mohan A, Chieng CH, Perera D, Clear D, Wong D, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study[J]. Clin Infect Dis. 2007;44(5):646&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">17278054</ArticleId></ArticleIdList></Reference><Reference><Citation>Premanand B, Kiener TK, Meng T, Tan YR, Jia Q, Chow VT, Kwang J. Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1[J]. Antiviral Res. 2012;95(3):311&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">22691220</ArticleId></ArticleIdList></Reference><Reference><Citation>Le TV, Nguyen VT, Nguyen QH, Pham DT. Molecular epidemiology analysis of enterovirus 71 strains isolated in Dak Lak, Vietnam, 2011-2016[J]. J Med Virol. 2019;91(1):56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30132913</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sanden S, van der Avoort H, Lemey P, Uslu G, Koopmans M. Evolutionary trajectory of the VP1 gene of human enterovirus 71 genogroup B and C viruses[J]. J Gen Virol. 2010;91(Pt 8):1949&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pubmed">20375223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J, Li J, Wei W, Liu X, Liu G, Yang J, Zhang W, Yu XF. Determinants of EV71 immunogenicity and protection against lethal challenge in a mouse model[J]. Immunol Res. 2015;62(3):306&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26025091</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, He Y, Yang H, Zhu J, Xu X, Dong J, Zhu Y, Jin Q. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, people&#x2019;s republic of China[J]. J Clin Microbiol. 2005;43(8):3835&#x2013;3839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1233905</ArticleId><ArticleId IdType="pubmed">16081920</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna-Wakim R, Yasukawa LL, Sung P, Arvin AM, Gans HA. Immune responses to mumps vaccine in adults who were vaccinated in childhood[J]. J Infect Dis. 2008;197(12):1669&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561204</ArticleId><ArticleId IdType="pubmed">18419345</ArticleId></ArticleIdList></Reference><Reference><Citation>Desselberger U, Huppertz HI. Immune responses to rotavirus infection and vaccination and associated correlates of protection[J]. J Infect Dis. 2011;203:188&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071058</ArticleId><ArticleId IdType="pubmed">21288818</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CC, Lau SK, Zhou B, Zhang MX, Tsoi HW, Chan KH, Chen XC, Woo PC, Yuen KY. Emergence of enterovirus 71 &#x201c;double-recombinant&#x201d; strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71[J]. Arch Virol. 2010;155(9):1413&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087135</ArticleId><ArticleId IdType="pubmed">20549263</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E, Wain-Hobson S. The 30th anniversary of quasispecies. Meeting on &#x2018;Quasispecies: past, present and future&#x2019;[J]. EMBO Rep. 2009;10:444&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680878</ArticleId><ArticleId IdType="pubmed">19343047</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E, Martin V, Perales C, Escarmis C. Coxsackieviruses and quasispecies theory: evolution of enteroviruses[J]. Curr Top Microbiol Immunol. 2008;323:3&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">18357763</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Ying XL, Zhou SL, Han T, Huang H, Jin Q, Yang F, Sun QY, Sun XX. Characterization of the enterovirus 71 P1 polyprotein expressed in pichia pastor as a candidate vaccine[J]. Hum Vaccin Immunother. 2014;10(8):2220&#x2013;2226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4896795</ArticleId><ArticleId IdType="pubmed">25424925</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Li C, He D, Cheng T, Ge S, Shih JW, Zhao Q, Chen PJ, Zhang J, Xia N. Antigenic analysis of divergent genotypes human enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity[J]. Vaccine. 2013;31(2):425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">23088887</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Mo Z, Liang Z, Zhang Y, Li R, Ong KC, Wong KT, Yang E, Che Y, Wang J, et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations[J]. BMC Med. 2015;13:226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574357</ArticleId><ArticleId IdType="pubmed">26381232</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KY, Lin JJ, Chiu CH, Yang S, Tsao KC, Huang YC, Lin TY. A potent virus-specific antibody-secreting cell response to acute enterovirus 71 infection in children[J]. J Infect Dis. 2015;212(5):808&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">25712974</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei D, Griffiths E, Martin J. WHO working group meeting to develop WHO recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines[J]. Vaccine. 2020;38:4917&#x2013;4923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7327506</ArticleId><ArticleId IdType="pubmed">32418797</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson CS, McCall PR, Stern HA, Yang H, Topham DJ. Antigenic cartography of H1N1 influenza viruses using sequence-based antigenic distance calculation[J]. BMC Bioinform. 2018;19(1):51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5809904</ArticleId><ArticleId IdType="pubmed">29433425</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X, Dong L, Lan Y, Peng Y, Wu A, Zhang Y, Huang W, Wang D, Wang M, Guo Y, et al. Mapping of H3N2 influenza antigenic evolution in China reveals a strategy for vaccine strain recommendation[J]. Nat Commun. 2012;3:709.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chen JS. Predicting antigenic variants of influenza A/H3N2 viruses[J]. Emerg Infect Dis. 2004;10:1385&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3320420</ArticleId><ArticleId IdType="pubmed">15496238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C, Cai Z, Zou Y, Zhang Z, Chen W, Deng L, Du X, Wu A, Yang L, Wang D, et al. FluPhenotype-a one-stop platform for early warnings of the influenza a virus[J]. Bioinf. 2020;36(10):3251&#x2013;3253.</Citation><ArticleIdList><ArticleId IdType="pubmed">32049310</ArticleId></ArticleIdList></Reference><Reference><Citation>Luksza M, Lassig M. A predictive fitness model for influenza[J]. Nature. 2014;507:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24572367</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Van Tan L, Luo K, Liao Q, Wang L, Qiu Q, Zou G, Liu P, Anh NT, Hong NT, et al. Genetic variation of multiple serotypes of enteroviruses associated with hand, foot and mouth disease in Southern China[J]. Virol Sin. 2021;36(1):61&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385209</ArticleId><ArticleId IdType="pubmed">32725479</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>